Wednesday, November 7, 2018

10 a.m. – 8 p.m.  Registration
Location: L St. Bridge

**IMMUNE ESCAPE: CURRENT UNDERSTANDING OF MECHANISMS AND ADVANCES IN THERAPEUTICS APPROACHES**

Location: East Salon ABC

2 – 2:05 p.m.  **Introduction**
Daniel S. Chen, MD, PhD – IMG Biosciences

**Session I: Therapeutic Strategies to Overcome Immune Resistance**

2:05 – 2:25 p.m.  **Mechanisms of Immune Escape to Checkpoint Inhibitors**
Priti Hegde, PhD – Genentech

2:25 – 2:40 p.m.  **A Novel Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy**
Brent A. Hanks, MD, PhD – Duke University Medical Center

2:40 – 2:55 p.m.  **Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-small Cell Lung Cancer**
Grace Dy, MD – Roswell Park Comprehensive Cancer Center

2:55 – 3:10 p.m.  **Melanoma Tissue Microarray Characterization with Digital Spatial Profiling Identifies Biomarkers of Clinical Response to Immunotherapy**
David Rimm, MD, PhD – Yale University

3:10 – 3:25 p.m.  **Primary and Secondary Mechanisms of Resistance to Autologous Anti-CD19 CAR T cell Therapy in Refractory Non-Hodgkin’s Lymphoma (rNHL)**
John Rossi, MD – Kite Pharma

3:25 – 3:45 p.m.  **Group Discussion**

3:45 – 4:00 p.m.  **Break**
4:00 – 5:00 p.m. Panel Discussion: Can CAR T cells Overcome and Influence Resistance to Other Treatment Modalities & New Concepts in Immune Checkpoints Blockade Designed to Overcome Local Immune Resistance
Co-Moderators: Adrian Bot, PhD – Kite a Gilead Company
Eric H. Rubin, MD – Merck
Panelists: Daniel S. Chen, MD, PhD – IMG Biosciences
Gordon J. Freeman, PhD – Dana-Farber Cancer Institute
Carl H. June, MD – University of Pennsylvania
Alan Korman, PhD – Bristol-Myers Squibb
Marcela Maus, MD, PhD – Massachusetts General Hospital

Session II: Underlying Mechanisms of Immune Escape

5:00 – 5:15 p.m. Analysis of TIL from Human Carcinoma Combined with Tissue Imaging and in vitro Models Uncovers Tumor-inflicted T Cell Deviations Related to Immune Escape and Strategies of Intervention
Elfriede Noessner, PhD – Helmholtz Zentrum Munchen

5:15 – 5:30 p.m. Impact of Tumor Inherent Interferons on Immune Reactivity and Personalized Therapy in Triple Negative Breast Cancer
Natasha K. Brockwell, BBiomed (Hons) – La Trobe Institute for Molecular Science

5:30 – 5:45 p.m. Repurposing Anti-Pathogen Vaccines to Overcome Immune Escape within the Tumor Microenvironment
Andrew Zloza, MD, PhD – Rutgers Cancer Institute of New Jersey

5:45 – 6:00 p.m. First in Human Data in Advanced Solid Tumors of NANT Cancer Vaccine: A Novel Temporospatial Orchestration of the Innate (NK) & Adaptive Immune System to Induce Antigen Cascade & Immunogenic Cell Death
Patrick Soon-Shiong – NANT Cancer Immunotherapy, Inc.

6:00 – 6:20 p.m. Group Discussion

6:20 – 6:35 p.m. Break
6:35 – 7:35 p.m.  **Panel Discussion: Using Oncolytic Immunotherapy to Overcome Immune Resistance in the Tumor Microenvironment & Immune Resistance and the Tumor Microenvironment**
*Co-Moderators:* Alessandra Cesano, MD, PhD – NanoString Inc.
Howard L. Kaufman, MD, FACS – Replimune Group Inc.
*Panelists:* Robert Coffin, PhD – Replimune Group Inc.
George Coukos, MD, PhD – University of Lausanne
Francesco M. Marincola, MD – Refuge Biotechnologies
Ira Mellman, PhD – Genentech
Ryan Sullivan, MD – Massachusetts General Hospital
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

7:35 – 7:55 p.m.  **Underlying Mechanisms of Immune Escape**
Thomas F. Gajewski, MD, PhD – University of Chicago

7:55 – 8 p.m.  **Closing**
Salil Patel, PhD – Bristol-Myers Squibb

8 – 9 p.m.  **Industry Networking Reception**

*Location:* East Salon Foyer
Thursday, November 8, 2018

6:30 – 7 p.m.  Registration
Location:  L St. Bridge

6:30 – 8 a.m.  Breakfast
Location:  Hall E Foyer

PRIMER ON TUMOR IMMUNOLOGY AND CANCER IMMUNOTHERAPY™

Location:  East Salon ABC

8 – 8:05 a.m.  Introduction
Timothy NJ Bullock, PhD – University of Virginia

Session I: Generating Anti-Tumor Immunity

8:05 – 8:35 a.m.  Adaptive Immunity to Tumors: Laying the Foundation for Immunotherapy
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

8:35 – 9:05 a.m.  Dendritic Cells
Tyler Curiel, MD – UT Health San Antonio

9:05 – 9:35 a.m.  Harnessing Natural Killer Cells to Potentiate Antitumor Immunity
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

9:35 – 9:55 a.m.  Panel Discussion

9:55 – 10:10 a.m.  Break

Session II: Breaking Through the Barriers – Passive Immunotherapy

10:10 – 10:15 a.m.  Introduction
Timothy NJ Bullock, PhD – University of Virginia

10:15 – 10:45 a.m.  Cancer Vaccines: From Ex Vivo Production to In Vivo Vaccination
Tanja de Gruijl, PhD – VU University Medical Center

10:45 – 11:15 a.m.  Monoclonal Antibodies and Their Derivatives
Charles G. Drake, MD, PhD – Columbia University Medical Center

11:15 – 11:45 a.m.  Cytokines
Kim A. Margolin, MD – City of Hope
11:45 – 12:05 p.m.  
**Panel Discussion**

12:05 – 1:05 p.m.  
**Lunch**

*Location:*  
101

**Session III: Analysis of Resistance and Response**

1:05 – 1:10 p.m.  
**Introduction**  
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

1:10 – 1:40 p.m.  
**Mechanisms of Extrinsic Resistance: A Miserable Microenvironment**  
Michael A. Curran, PhD – *University of Texas MD Anderson Cancer Center*

1:40 – 2:10 p.m.  
**Mechanisms of Resistance: Checkpoint Receptors**  
Julie R. Brahmer, MD – *Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins*

2:10 – 2:40 p.m.  
**A High-dimensional Assay and Analysis Platform to Discover Immune Correlates of Cancer Immunotherapy**  
Sacha Gnjatic, PhD – *Icahn School of Medicine at Mount Sinai*

2:40 – 3:10 p.m.  
**Panel Discussion**

3:10 – 3:25 p.m.  
**Break**

**Session IV: Current IO Immunotherapy**

3:25 – 3:30 p.m.  
**Introduction**  
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*

3:30 – 4 p.m.  
**Adoptive Cell Therapy**  
Patrick Hwu, MD – *University of Texas MD Anderson Cancer Center*

4 – 4:30 p.m.  
**Combination Therapies**  
Leisha A. Emens, MD, PhD – *University of Pittsburgh*

4:30 – 4:50 p.m.  
**Panel Discussion**

4:50 – 5 p.m.  
**Closing**  
Jonathan Powell, MD, PhD – *Johns Hopkins University School of Medicine*
Thursday, November 8, 2018

6:30 a.m. – 7 p.m.  
Registration  
Location: L St. Bridge

6:30 – 8 a.m.  
Breakfast  
Location: Hall E Foyer

WORKSHOP ON NUTRITION, METABOLISM AND THE MICROBIOME IN CANCER THERAPY

Location: 202AB

8 – 8:05 a.m.  
Introduction  
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

Session I: The Impact of the Microbiome on Cancer Therapy

8:05 – 8:30 a.m.  
The Evolving Role of the Microbiome on Response to Cancer Therapy  
Laurence Zitvogel, MD, PhD – Institute Gustave Roussy

8:30 – 9 a.m.  
Mechanistic Insights Into the Influence of Gut Microbiota on Anti-Tumor Immunity  
Thomas F. Gajewski, MD, PhD – University of Chicago

9 – 9:30 a.m.  
The Microbiome as a Biomarker and a Therapeutic Target  
Jennifer Wargo, MD, MMSc - University of Texas MD Anderson Cancer Center

9:30 – 9:45 a.m.  
Panel Discussion  
Moderator: Laurence Zitvogel, MD, PhD – Institute Gustave Roussy  
Panelists: Thomas F. Gajewski, MD, PhD – University of Chicago  
Jennifer Wargo, MD, MMSc - University of Texas MD Anderson Cancer Center

9:45 – 10 a.m.  
Break

Session II: Interplay of Nutrition, Metabolism, and the Microbiome

10 – 10:30 a.m.  
The Influence of Nutrition on the Microbiome and Immune Function  
Guido Kroemer, MD, PhD – Institute Gustave Roussy

10:30 – 11 a.m.  
Harnessing Diet and the Microbiome for Cancer Patients and Survivors  
Carrie Daniel-MacDougall, MPH, PhD – University of Texas MD Anderson Cancer Center
11 – 11:30 a.m.    **Homeostatic and Inflammatory Immune Responses to Human Microbiotas in Gnotobiotic Mice**

Graham Britton, PhD –  *Icahn School of Medicine at Mount Sinai*

11:30 a.m. – 12 p.m.    **The Interplay Between Diet, Intestinal Microbiota and Colorectal Cancer**

Christian Jobin, PhD –  *University of Florida*

12 – 1 p.m.    **Panel Discussion**

Graham Britton, PhD –  *Icahn School of Medicine at Mount Sinai*

Carrie Daniel-MacDougall, MPH, PhD –  *University of Texas MD Anderson Cancer Center*

Thomas F. Gajewski, MD, PhD –  *University of Chicago*

Christian Jobin, PhD –  *University of Florida*

Guido Kroemer, MD, PhD –  *Institute Gustave Roussy*

Jennifer Wargo, MD, MMSc -  *University of Texas MD Anderson Cancer Center*

Laurence Zitvogel, MD, PhD –  *Institute Gustave Roussy*
Thursday, November 8, 2018

6:30 a.m. – 7 p.m.  Registration
Location:  L St. Bridge

6:30 – 8 a.m.  Breakfast
Location:  Hall E Foyer

**FDA/SITC Co-Sponsored Workshop**

*Immune-modified Response Criteria in Cancer Immunotherapy Clinical Trials*

Location:  202AB

2 – 2:10 p.m.  Introduction
Marc Theoret, MD – U.S. Food & Drug Administration, OHOP
Howard Kaufman, MD, FACS – Replimune Group Inc.

Session I: Pseudoprogression with Immuno-oncology Therapeutics - Current Challenges with Evaluation of Surrogate Endpoints with Immuno-oncology Drug Products

2:10 – 2:30 p.m.  Pseudoprogression and Current Clinical Challenges in the Management of Patients on Immuno-oncology Therapy
Kim A. Margolin, MD – City of Hope

2:30 – 2:50 p.m.  Immune-Modified Response Criteria in Clinical Development Programs of Immuno-oncology Therapeutics
Sanjay Goel, MD – Montefiore Medical Center

2:50 – 3:10 p.m.  Regulatory Perspectives with Use of Immune-Modified Response Criteria for Assessment of Surrogate Clinical Efficacy Endpoints for Registration Trials
Patricia Keegan, MD – U.S. Food & Drug Administration

3:10 – 3:55 p.m.  Panel Discussion
Moderator: Marc Theoret, MD – U.S. Food & Drug Administration, OHOP
Panelists: Peter F. Bross, MD – U.S. Food and Drug Administration, CBER
David Feltquate, MD, PhD – Bristol-Myers Squibb
Sanjay Goel, MD – Montefiore Medical Center
Patricia Keegan, MD – U.S. Food & Drug Administration
Kim A. Margolin, MD – City of Hope
Lawrence H. Schwartz, MD – Columbia University College of Physicians and Surgeons
Steven Silverstein, MBA – Melanoma Research Foundation
Jon Wigginton, MD – MacroGenics, Inc.
3:55 – 4:10 p.m. Break

Session II: Evaluating Surrogate Endpoints for Immuno-Oncology Drug Development: “New and Renewed” Concepts and Perspectives

4:10 – 4:30 p.m. Clinical Trial Endpoints Considerations for Evaluating Efficacy in Immuno-Oncology Clinical Trials
David McDermott, MD – Beth Israel Deaconess Medical Center

4:30 – 4:50 p.m. Beyond Conventional Tumor-Based Measurements: Analysis Considerations for Clinical Efficacy Endpoints to More Fully Capture the Benefit of Immuno-Oncology Therapeutics
Rajeshwari Sridhara, PhD – U.S. Food & Drug Administration

4:50 – 5:10 p.m. How to Integrate Biomarkers and Other Correlates of Response into the Regulatory Landscape
Genevieve Boland, MD, PhD – Massachusetts General Hospital

5:10 – 5:55 p.m. Panel Discussion
Moderator: Howard Kaufman, MD, FACS – Replimune Group Inc.
Panelists: Genevieve Boland, MD, PhD – Massachusetts General Hospital
Samir Khleif, MD – Georgetown University
Ke Liu, MD, PhD – U.S. Food and Drug Administration, CBER
David McDermott, MD – Beth Israel Deaconess Medical Center
Reena Philip, PhD – U.S. Food & Drug Administration
Meredith Regan, ScD – Dana-Farber Cancer Institute
Lawrence H. Schwartz, MD – Columbia University College of Physicians and Surgeons
Rajeshwari Sridhara, PhD – U.S. Food & Drug Administration

5:55 – 6 p.m. Closing
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Ke Liu, MD, PhD – U.S. Food and Drug Administration, CBER
Thursday, November 8, 2018

6:30 a.m. – 7 p.m.  Registration
Location: L St. Bridge

6:30 – 8 a.m.  Breakfast
Location: Hall E Foyer

GRANT WRITING: FROM START TO FINISH, AND THEN STARTING AGAIN

Location: 204BC

6:30 – 6:35 p.m.  Introduction
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

6:35 – 6:55 p.m.  Obtaining Funding in Academia - Identifying and Selecting the Appropriate Grant
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

6:55 – 7:15 p.m.  Obtaining Funding in Academia - Mechanics of Grant Writing
Thomas F. Gajewski, MD, PhD – University of Chicago

7:15 – 7:35 p.m.  NIH/NCI Grants: The NIH Grant Review Process
Denise Shaw, PhD – National Institutes of Health

7:35 – 7:55 p.m.  Melanoma Research Alliance (MRA)/Foundation Funding
Kristen Mueller, PhD – Melanoma Research Alliance

7:55 – 8:25 p.m.  Panel Discussion

8:25 – 8:30 p.m.  Closing
Ana Carrizosa Anderson, PhD – Harvard Medical School

8:30 – 9:30 p.m.  Grant Writing Workshop Reception
Location: 204A
Thursday, November 8 – Sunday, November 11, 2018

33rd ANNUAL MEETING

Thursday, November 8, 2018

6:30 a.m. – 7 p.m.  Registration  L St. Bridge

5 – 6:30 p.m.  33rd Annual Meeting Opening Reception  Hall E

8:30 – 9:30 p.m.  SITC Sparkathon Alumni Reception  Marriott Marquis, Cherry Blossom

9 – 11 p.m.  Early Career Scientist Networking Reception  The Dignitary at Marriott Marquis

Friday, November 9, 2018

6:30 a.m. – 7 p.m.  Registration  L St. Bridge

7:15 – 8 a.m.  Presidential Champagne Breakfast & Membership Business Meeting  Hall D

7:30 – 8:30 a.m.  Breakfast  Hall E Foyer

8 – 8:05 a.m.  Presidential Welcome  Lisa H. Butterfield, PhD – University of Pittsburgh  Hall D

Session 100: Update Session
Location:  Hall D

8:05 – 8:20 a.m.  Food & Drug Administration Update: Cell and Gene Therapy  Raj Puri, MD, PhD – Food & Drug Administration
8:20 – 8:35 a.m.  
**Stand Up To Cancer Update**  
Carl H. June – *University of Pennsylvania*

**Session 101: Keynote Address**  
*Location:* Hall D

8:35 – 8:40 a.m.  
**Introduction**  
Lisa H. Butterfield, PhD – *University of Pittsburgh*

8:40 – 9:20 a.m.  
**Next Gen T Cell-based Immunotherapy**  
Nicholas P. Restifo, MD – *National Cancer Institute*

9:20 – 9:25 a.m.  
**Q&A**  
Nicholas P. Restifo, MD – *National Cancer Institute*

**Session 102: Understanding the Tumor Microenvironment**  
*Co-Chairs:*  
Bernard A. Fox, PhD – *Earle A. Chiles Research Institute, Robert W. Franz Cancer Center*  
Stefani Spranger, PhD – *Koch Institute for Integrative Cancer Research at MIT*

*Location:* Hall D

9:25 – 9:30 a.m.  
**Introduction**  
Bernard A. Fox, PhD – *Earle A. Chiles Research Institute, Robert W. Franz Cancer Center*

9:30 – 9:50 a.m.  
**Genomic Approaches to the Tumor Microenvironment**  
Alexandra Snyder Charen, MD – *Merck*

9:50 – 10:10 a.m.  
**Understanding the Tumor Immune Composition Using Quantitative and Spatially Resolved Imaging Mass Cytometry**  
Kurt A. Schalper, MD, PhD – *Yale School of Medicine*

10:10 – 10:25 a.m.  
**Break**

10:25 – 10:45 p.m.  
**Single Cell Genomics – Using a Finer Lens to Unravel Features of Human Immunity**  
Alexandra-Chloe Villani, PhD – *Harvard Medical School*

10:45 – 11:05 a.m.  
**Mouse Models of the TME**  
Tyler Jacks, PhD – *Koch Institute for Integrative Cancer Research at MIT*

11:05 – 11:20 a.m.  
**Reinvigorating TILs by hyper-oxygenation**  
Tomasz Zal, PhD – *MD Anderson Cancer Center*

11:20 – 11:35 a.m.  
**Comparison of biomarker assay modalities in anti-PD-(L)1 monotherapy: a meta-analysis**  
Steve Lu, BS – *John Hopkins University School of Medicine*
11:35 – 11:55 a.m.  Panel Discussion

11:55 a.m. – 12 p.m.  Closing
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Session 103: Late-Breaking Abstract Session
Chair: Crystal Mackall, MD – Stanford University

Location: Hall D

12 – 12:15 p.m.  Imaging of tumor infiltrating T cells with an anti-CD8 minibody 89Zr-IAB22M2C in advanced solid tumors: a phase I first-in-human study
Michael Gordon, MD – HonorHealth Research Institute

12:15 – 12:30 p.m.  In silico assessment of variation in TMB quantification across diagnostic platforms: Phase 1 of the Friends of Cancer Research Harmonization Project
David Fabrizio, PhD – Foundation Medicine

12:30 – 12:45 p.m.  Sparkathon Update: Team TimIOs – A Pooled Analysis of Durable versus Transient Responders on Immunotherapy Trials
Yana Najjar, MD – University of Pittsburgh
Randy Sweiss, MD – University of Chicago

12:45 – 2:15 p.m.  Lunch; Poster Viewing & Exhibits
Location: Hall E

Rapid Oral Abstract Presentation Session
Co-Chairs:
Sebastiano Battaglia, PhD – Roswell Park Comprehensive Cancer Institute
Claire Vanpouille-Box, PhD – Weill Cornell Medical College

Location: 204ABC

1 – 1:05 p.m.  High-dimensional flow cytometry of circulating immune cells predicts clinical responses to combination Immune Checkpoint Blockade (ICB) and Radiotherapy (RT) in Gastroesophageal Cancer (GEC)
Joseph Chao, MD – City of Hope Comprehensive Cancer Center

1:05 – 1:10 p.m.  Fast quality gauging of tumor-infiltrating lymphocytes (TIL) for the treatment of patients with solid cancer
Georgia Paraschoudi, M.Sc. – Champalimaud Foundation

1:10 – 1:15 p.m.  Immunologic biomarkers in a multi-center, single arm, open label Phase II clinical trial of mFOLFOX6 and pembrolizumab in patients with advanced colorectal cancer
Matthew Farren, PhD – Emory University
1:15 – 1:20 p.m. Deep learning of the immune synapse

1:20 – 1:25 p.m. Overcoming genetically-based resistance mechanisms to PD-1 blockade
Davis Torrejon, MD – UCLA Hematology-Oncology

1:25 – 1:30 p.m. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang, MD, PhD – University of Texas MD Anderson Cancer Center

1:30 – 1:35 p.m. Abstract Presentation

1:35 – 1:40 p.m. Development of a next-generation sequencing-based microsatellite instability assay (MSI-NGS) for solid tumor testing
Sean Glenn, PhD – Omniseq, Inc.

1:40 – 1:45 p.m. Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment
Sekwon Jang, MD – iNova/Personalis

1:45 – 1:50 p.m. Preinfusion product doubling time is associated with CAR T cell expansion and outcomes in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma
Frederick L. Locke, MD – Moffitt Cancer Center

1:50 – 1:55 p.m. DuoBody-PD-L1x4-1BB combines checkpoint blockade and 4-1BB co-stimulation to promote antigen-specific T-cell stimulation and proliferation
Isil Altintas, PhD – Genmab

1:55 – 2 p.m. Molecular determinants of response to PD-L1 blockade across tumor types
Romain Banchereau – Genentech

2 – 2:05 p.m. CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule
Alexandre E. Michaux, PhD – Celyad SA

Concurrent Session 104: Immune Checkpoints – Beyond PD-1
Co-Chairs:
Ana Carrizosa Anderson, PhD – Harvard Medical School
Charles G. Drake, MD, PhD – Columbia University Medical Center
Location: Hall D

2:15 – 2:20 p.m. Introduction
Ana Carrizosa Anderson, PhD – Harvard Medical School
2:20 – 2:45 p.m.  **LAG-3: Signaling, Function and Potential Impact on Cancer Immunotherapy**  Dario A.A. Vignali, PhD – *University of Pittsburgh*

2:45 – 3:10 p.m.  **The Influence of the Cancer Genome on Efficacy of Immunotherapy in Lung Cancer**  Brian Ruffell, PhD – *Moffitt Cancer Center*

3:10 – 3:25 p.m.  **Break**

3:25 – 3:50 p.m.  **Targeting the TIGIT/CD226 Axis in Cancer Immunotherapy**  Hassane M. Zarour, MD – *UPMC Hillman Cancer Center*

3:50 – 4:15 p.m.  **4-1BB and Metabolism**  Ignacio Melero, MD, PhD – *Clinica Universidad de Navarra-FIMA*

4:15 – 4:30 p.m.  **Remodeling the tumor microenvironment – Targeting Scavenger receptors**  Dhifaf Sarhan, PhD – *Karolinska Institutet*

4:30 – 4:45 p.m.  **Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding**  Lawrence P. Andrews, PhD – *University of Pittsburgh*

4:45 – 4:50 p.m.  **Closing**  Charles G. Drake, MD, PhD – *Columbia University Medical Center*

**Concurrent Session 105: Early Phase 1 Clinical Trials**

Co-Chairs:  
David S. Hong, MD – *University of Texas MD Anderson Cancer Center*  
Patricia LoRusso, DO – *Yale University*

*Location:* East Salon ABC

2:15 – 2:20 p.m.  **Introduction**  
David S. Hong, MD – *University of Texas MD Anderson Cancer Center*

2:20 – 2:35 p.m.  **Phase 1 study using mogamulizumab (KW-0761) to deplete regulatory T cells in combination with checkpoint inhibitors durvalumab (MEDI4736) or tremelimumab in subjects with advanced solid tumors**  
Dmitriy Zamarin, MD, PhD – *Memorial Sloan Kettering Cancer Center*

2:35 – 2:50 p.m.  **First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers**  
Timothy Yap, MD – *University of Texas MD Anderson Cancer Center*
2:50 – 3 p.m. **Expert Discussant**  
Zihai Li, MD, PhD – MUSC Hollings Cancer Center

3 – 3:15 p.m. **The GAPVAC approach of actively personalized peptide vaccination for patients with newly diagnosed glioblastoma**  
Hideho Okada, MD, PhD – University of California, San Francisco, USA and Parker Institute for Cancer Immunotherapy

3:15 – 3:30 p.m. **The Personal Vaccine, NEO-PV-01 with anti-PD1, Induces Neoantigen-Specific De Novo Tumor-Related Immunity in Patients with Advanced Cancer**  
Siwen Hu-Lieskovan, MD, PhD – Ronald Reagan UCLA Medical Center

3:30 – 3:40 p.m. **Expert Discussant**  
Drew Pardoll, MD, PhD – Johns Hopkins University

3:40 – 3:55 p.m. **A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma**  
Diwakar Davar, MD – University of Pittsburgh Department of Medicine

3:55 – 4:10 p.m. **Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, ettilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma**  
Adnam Khattak, MD – Perth University

4:10 – 4:25 p.m. **The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study**  
Nehal Lakhani, MD, PhD – START-Midwest

4:25 – 4:40 p.m. **Phase 1 dose-finding study of the anti–TIGIT antibody MK-7684 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors**  
Talia Golan – Sheba Medical Center

4:40 – 4:50 p.m. **Expert Discussant**  
Aung Naing, MD, FACP – University of Texas MD Anderson Cancer Center

4:50 – 5:05 p.m. **Break**
Concurrent Session 106: Cytokines Reinvented
Co-Chairs:
James L. Gulley, MD, PhD, FACP – National Cancer Institute
Darrell J. Irvine, PhD – Massachusetts Institute of Technology

Location: Hall D

5:05 – 5:07 p.m. Introduction
James Gulley, MD, PhD, FACP – National Cancer Institute

5:07 – 5:27 p.m. NHS/IL15
Marijo Bilusic, MD, PhD – National Cancer Institute, National Institutes of Health

5:27 – 5:47 p.m. Harnessing Potent Immune Agonist Pathways through Kinetic Engineering
Deborah Charych, PhD

5:47 – 6:07 p.m. Locoregional Cytokine Immunotherapy
K. Dane Wittrup, PhD – Massachusetts Institute of Technology

6:07 – 6:17 p.m. Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma
Adi Diab, MD – The University of Texas MD Anderson Cancer Center

6:17 – 6:27 p.m. Decoy-resistant Interleukin-18 overcomes the soluble immune checkpoint IL-18BP to unlock a potent immunotherapeutic cytokine pathway
Aaron Ring – Yale School of Medicine

6:27 – 6:30 p.m. Closing
Darrell J. Irvine, PhD – Massachusetts Institute of Technology

Concurrent Session 107: Metabolic Manipulation of the TME
Co-Chairs:
Greg M. Delgoffe, PhD – University of Pittsburgh
Michele W. Teng, PhD – QIMR Berghofer Medical Research Institute

Location: East Salon ABC

5:05 – 5:25 p.m. Targeting the Adenosinergic Pathway to Improve Combination Immunotherapy
Michele W. Teng, PhD – QIMR Berghofer Medical Research Institute

5:25 – 5:45 p.m. Enhancement of Oncolytic Virus Immunotherapy Through Vector-Encoded Metabolic Modulation of the Tumor Microenvironment
Greg M. Delgoffe, PhD – University of Pittsburgh
5:45 – 6 p.m.  Chronic endoplasmic reticulum stress drives mitochondrial exhaustion of CD8 TILs
Jessica Thaxton, PhD MSCR – Medical University of South Carolina

6 – 6:15 p.m.  Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
Esra Akbay, PhD – University of Texas Southwestern Medical

6:15 – 6:30 p.m.  Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Ashley Menk, BS – University of Pittsburgh

6:30 – 8 p.m.  Poster Reception
Location:  Hall E
Saturday, November 10, 2018

7 a.m. – 7 p.m. Registration
Location: L St. Bridge

7 – 8 a.m. Breakfast
Location: Hall E Foyer

7:20 – 7:25 a.m. Annual Meeting Organizer Welcome
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital
Location: Hall D

Session 200: Update Session
Location: Hall D

7:25 – 7:40 a.m. Policy Committee Update
Samir N. Khleif, MD – Georgetown University

Session 201: Smalley Keynote
Location: Hall D

7:40 – 7:45 a.m. Introduction
Lisa H. Butterfield, PhD – University of Pittsburgh

7:45 – 8:25 a.m. Engineering T cells to Effectively Target Tumors and Overcome Obstacles To Achieving Tumor Eradication
Philip D. Greenberg, MD – Fred Hutchinson Cancer Research Center

8:25 – 8:30 a.m. Q&A
Philip D. Greenberg, MD – Fred Hutchinson Cancer Research Center

Session 202: Cell-Based Therapies for Solid Tumors
Co-Chairs:
Chantale Bernatchez, PhD – University of Texas MD Anderson Cancer Center
Mitchell Cairo, MD – New York Medical College At Maria Fareri Children’s Hospital
Crystal Mackall, MD – Stanford University
Location: Hall D

8:30 – 8:35 a.m. Introduction
Crystal Mackall, MD – Stanford University
8:35 – 8:55 a.m. | Pre-Clinical Approaches to CAR NK cell Therapy in Neuroblastoma and Sarcomas
Mitchell S. Cairo, MD – New York Medical College at Maria Fareri Children’s Hospital

8:55 – 9:15 a.m. | CAR T cell Therapies in Glioblastoma
Christine Brown, PhD – City of Hope National Medical Center

9:15 – 9:30 a.m. | Break

9:30 – 9:50 a.m. | CAR T cell Therapies in Solid Tumors
Gianpietro Dotti, MD – University of North Carolina, Chapel Hill

9:50 – 10:10 a.m. | TIL Therapy for Melanoma and Beyond – Lessons Learned on Optimal Tumor Rejection Antigens for Solid Tumors
Steven A. Rosenberg, MD, PhD – National Cancer Institute, National Institutes of Health

10:10 – 10:25 a.m. | Tscm-like CD8+ T-cells are Associated with Adoptive TIL Therapy Response and Survival
Matthew Beatty, PhD – Moffitt Cancer Center

10:25 – 10:40 a.m. | Next-generation retroviral vector with membrane-anchored IL-12 to improve adoptive T cell immunotherapy and enhance its safety
Ling Zhang, PhD – National Institutes of Health

10:40 – 11 a.m. | Panel Discussion

11 – 11:05 a.m. | Closing
Chantale Bernatchez, PhD – University of Texas MD Anderson Cancer Center

Concurrent Session 203: Update Session
Location: Hall D

11:05 – 11:35 a.m. | National Cancer Institute Update: Immuno-oncology Research at the National Cancer Institute
Norman E. Sharpless, MD – National Cancer Institute

Concurrent Session 204: Clinical Management of Cell Therapy Administration
Co-Chairs:
Harriet Kluger, MD – Yale University
Krista Rubin, MS, FNP-BC – Massachusetts General Hospital

Location: East Salon ABC

11:05 – 11:10 a.m. | Introduction
Harriet Kluger, MD – Yale University
11:10 – 11:30 a.m.  Tumor Infiltrating Lymphocytes
Ronnie Shapira-Frommer, MD – Ella Institute for Immuno-Oncology

11:30 – 11:50 a.m.  Clinical and Biomarker Correlates and Management of Common Cellular Therapy Toxicities Including Cytokine Release Syndrome and Neurotoxicity
Eric L. Smith, MD, PhD – Memorial Sloan Kettering Cancer Center

11:50 a.m. – 12:10 p.m.  CAR T Cell Therapy in Pediatric Cancer Treatment
Shannon L. Maude, MD, PhD – Children's Hospital of Philadelphia Center for Childhood Cancer Research

12:10 – 12:25 p.m.  Q&A

12:25 – 12:30 p.m.  Closing
Krista Rubin, MS, FNP-BC – Massachusetts General Hospital

Concurrent Session 205: Late-Breaking Abstract Session
Chair: Naiyer A. Rizvi, MD – Columbia University Medical Center

Location: Hall D

11:35 – 11:50 a.m.  Pembrolizumab in combination with chemoradiotherapy (CRT) in human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)
Steven F. Powell, MD – Sanford Cancer Center

11:50 a.m. – 12:05 p.m.  Expert Discussant
Charles Drake, MD, PhD – Columbia University Medical Center

Concurrent Session 206: SITC Sparkathon Update

Location: Hall D

12:05 – 12:20 p.m.  Team METIOR Incubator: Strengthening Communication Across Scientific Disciplines
Alexandra Cadena, BS/BA – MD Anderson Cancer Center
Sebastiano Battaglia, PhD – Roswell Park Cancer Institute

12:20 – 1:50 p.m.  Lunch; Poster Viewing & Exhibits
Location: Hall E
Rapid Oral Abstract Presentation Session
Chair:
Julie Decock, PhD – Qatar Biomedical Research Institute

Location: 204ABC

12:35 – 12:40 p.m. Pharmacodynamic Activity of MEDI1873, a Glucocorticoid-Induced Tumor Necrosis Factor Family-Related protein (GITR) Agonist Molecule, Administered Intravenously to Patients with Advanced Solid Tumors
Nicholas Durham, PhD – MedImmune

12:40 – 12:45 p.m. Intratumoral injection of a novel oncolytic virus, Voyager V1 (VV1): completed phase 1 monotherapy in patients with refractory solid tumors
Steven Powell, MD – Sanford Cancer Center

12:45 – 12:50 p.m. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
Kohei Shitara, MD – National Cancer Hospital East

12:50 – 12:55 p.m. Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody, in advanced solid tumors
Sunil Sharma, MD – Honor Health Research Institute

12:55 – 1 p.m. A phase 1 study of ALX148: CD47 blockade in combination with anticancer antibodies to bridge innate and adaptive immune responses for advanced malignancy
Nehal Lakhani, MD, PhD – START Midwest

1 – 1:05 p.m. Phase I dose-finding study of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced solid tumors or lymphomas
Funda Meric-Bernstam, MD – MD Anderson Cancer Center

1:05 – 1:10 p.m. Preliminary evidence of intratumoral activation and immunomodulatory effect of CX-072, a Probody therapeutic antibody prodrug targeting PD-L1, in a phase 1/2a trial
Luc R. Desnoyers, PhD – CytomX Therapeutics, Inc.

1:10 – 1:15 p.m. Preliminary Biomarker Analysis of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor
Kai He, MD, PhD

1:15 – 1:20 p.m. A phase 1b/2 trial of lenvatinib in combination with pembrolizumab in patients with non-small cell lung cancer
Marcia Brose – Abramson Cancer Center of the University
1:20 – 1:25 p.m. HyPeR: A Phase 1, Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation HypoMethylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours
Malaka Ameratunga, MBBS – Royal Marsden Hospital

1:25 – 1:30 p.m. Interleukin-6 gene expression is highly upregulated in immune checkpoint mediated enterocolitis
Daniel Johnson, MD – MD Anderson Cancer Center

1:30 – 1:35 p.m. Clinical efficacy of immune checkpoint inhibitors in patients with small cell lung cancer is associated with high tumor mutational burden and development of immune-related adverse events
Biagio Ricciuti, MD – Dana-Farber Cancer Institute

Session 207: Presidential Session
Location: Hall D

1:55 – 2 p.m. Introduction
Lisa H. Butterfield – University of Pittsburgh

2 – 2:15 p.m. PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy
Gabriel Abril-Rodriguez, MS – University of California, Los Angeles

2:15 – 2:30 p.m. Adaptive plasticity of IL10+ and IL35+ regulatory T cells and their cooperative regulation of anti-tumor immunity
Hiroshi Yano, BS – University of Pittsburgh

2:30 – 2:40 p.m. Expert Discussant
Nicholas P. Restifo, MD – National Cancer Institute

2:40 – 2:55 p.m. Endoplasmic reticulum stress-induced transcription factor C/EBP homologous protein (Chop) thwarts effector T cell activity in tumors through repression of T-bet
Yu Cao, PhD – H. Lee Moffitt Cancer Center & Research Institute

2:55 – 3:10 p.m. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors
Kristin Anderson, PhD – Fred Hutchinson Cancer Research Center

3:10 – 3:20 p.m. Expert Discussant
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center

3:20 – 3:35 p.m. Break
Concurrent Session 208: Advances in Immunotherapy of Breast and Gynecologic Cancers
Co-Chairs:
George Plitas, MD – Memorial Sloan Kettering Cancer Center
Alessandro Santin, MD – Yale School of Medicine

Location: Hall D

3:35 – 3:40 p.m. Introduction
George Plitas, MD – Memorial Sloan Kettering Cancer Center

3:40 – 4:05 p.m. Advances in Immunotherapy of Gynecologic Malignancies
Dmitriy Zamarin, MD, PhD – Memorial Sloan Kettering Cancer Center

4:05 – 4:30 p.m. Breast Cancer
Sylvia Adams, MD – New York University Cancer Institute

4:30 – 4:45 p.m. Increased tumor-resident memory T cells in breast cancer is associated with improved prognosis
Paul Neeson, PhD – Peter MacCallum Cancer Centre

4:45 – 5 p.m. Tumor infiltrating lymphocyte recruitment after peri-lymphatic IRX-2 cytokine immunotherapy in resectable breast cancer and head and neck carcinoma
David Page, MD – Providence Portland Medical Center

Concurrent Session 209: Advances in Immunotherapy of GI and Pancreatic Cancer
Co-Chairs:
Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Herbert J. Zeh, MD – UT Southwestern Medical Center

Location: 206

3:35 – 3:40 p.m. Introduction
Dung T. Le, MD – The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

3:40 – 3:55 p.m. Augmenting T cell Immunity in Pancreatic Cancer
Stephanie K. Dougan, PhD – Dana-Farber Cancer Institute

3:55 – 4:10 p.m. Reprograming the Pancreatic Tumor Microenvironment to Improve Responses to Therapy
David G. DeNardo, PhD – Washington University School of Medicine, St. Louis

4:10 – 4:25 p.m. Exploiting the Complex Stromal Biology of Pancreas Cancer
Sunil R. Hingorani, MD, PhD – Fred Hutchinson Cancer Research Center
4:25 – 4:40 p.m.  **Immunotherapy in Hepatocellular Carcinoma (HCC)**  Kevin Staveley O’Carroll, MD, PhD, MBA – *University of Missouri*

4:40 – 4:55 p.m.  **Lipid accumulation in the pancreatic tumor microenvironment drives metabolic exhaustion of CD8+ T cells**  Teresa Manzo, PhD – *European Institute of Oncology, Milan*

4:55 – 5 p.m.  **Closing**  Herbert J. Zeh, MD – *UT Southwestern Medical Center*

**Concurrent Session 210: Advances in Immunotherapy of GU Tumors**

Co-Chairs:  
Arjun V. Balar, MD – Perlmutter Cancer Center – *New York University Langone Medical Center*  
Padmanee Sharma, MD, PhD – *University of Texas MD Anderson Cancer Center*

**Location:**  
202AB

3:35 – 3:40 p.m.  **Introduction**  
Arjun V. Balar, MD – Perlmutter Cancer Center – *New York University Langone Medical Center*

3:40 – 4 p.m.  **The Management of Urothelial Bladder Cancer in the Era of Cancer Immunotherapy**  
Arjun V. Balar, MD – Perlmutter Cancer Center - *New York University Langone Medical Center*

4 – 4:20 p.m.  **Clinical Genomics and Cancer Immunotherapy**  
Eliezer Van Allen, MD – *Dana-Farber Cancer Institute*

4:20 – 4:40 p.m.  **From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy**  
Padmanee Sharma, MD, PhD – *University of Texas MD Anderson Cancer Center*

4:40 – 4:55 p.m.  **Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444**  
Lawrence Fong, MD – *University of California*

4:55 – 5:00 p.m.  **Closing**  
Padmanee Sharma, MD, PhD – *University of Texas MD Anderson Cancer Center*
Concurrent Session 211: Advances in Immunotherapy of Hematologic Malignancies  
Co-Chairs:  
Joshua Brody, MD – Mount Sinai School of Medicine  
Elizabeth Shpall, MD – University of Texas MD Anderson Cancer Center  
Location:  
3:35 – 4 p.m. Off-The-Shelf Engineered NK Cells for The Treatment of Cancer  
Katayoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center  
4 – 4:25 p.m. CAR T cells  
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center  
4:25 – 4:45 p.m. Checkpoint Blockade  
Thomas Marron, PhD – Mount Sinai Hospital  
4:45 – 5 p.m. LSD1 Inhibition Promotes CD141Hi Dendritic Cell Differentiation in Myelodysplastic Syndromes  
Pragya Srivastava, PhD – Roswell Park Comprehensive Cancer Center  
5 – 5:10 p.m. Break

Concurrent Session 212: Advances in Immunotherapy of Lung, Head and Neck Cancer  
Co-Chairs:  
Naiyer A. Rizvi, MD – Columbia University Medical Center  
Tanguy Seiwert, MD – University of Chicago  
Location:  
3:35 – 3:40 p.m. Introduction  
Naiyer A. Rizvi, MD – Columbia University Medical Center  
3:40 – 4:05 p.m. The Influence of the Cancer Genome on Efficacy of Immunotherapy in Lung Cancer  
Nadeem Riaz, MD, MSc – Memorial Sloan Kettering Cancer Center  
4:05 – 4:30 p.m. Head and Neck Cancer  
Tanguy Seiwert, MD – University of Chicago  
Identification and profiling of neoantigen-specific T cells in NSCL cancer patients treated with atezolizumab  
Alessandra Nardin, DVM – immunoSCAPE  
4:30 – 4:45 p.m. Peripheral T cell dynamics in resectable NSCLC patients treated with neoadjuvant PD-1
blockade
Jiajia Zhang, MD – MPH – Johns Hopkins University

Concurrent Session 213: Advances in Immunotherapy of Pediatric Malignancies
Co-Chairs:
Kavita Dhodapkar, MD – Emory University
Crystal Mackall, MD – Stanford University
Location: 204ABC

3:35 – 3:40 p.m. Introduction
Kavita Dhodapkar, MD – Emory University

3:40 – 4 p.m. Preventing Relapse After CAR T cell Immunotherapy for B cell Malignancies
Terry J. Fry, MD – Children’s Hospital of Colorado

4 – 4:20 p.m. Vaccines Targeting Malignant Brain Tumors
Duane A. Mitchell, MD, PhD – University of Florida

4:20 – 4:40 p.m. Tumor Microenvironment
Kavita M. Dhodapkar, MD – Emory University

4:40 – 4:55 p.m. Characterization of anti-tumor immune responses and Effects on Survival of Neoadjuvant Oncolytic Virotherapy in spontaneous Osteosarcoma
Kelly Makielski, DVM, MS – University of Minnesota

4:55 – 5 p.m. Closing
Crystal Mackall, MD – Stanford University

Concurrent Session 214: Basic Biology of Tregs
Co-Chairs:
Sergio A. Quezada, PhD – University College London
Dario A.A. Vignali, PhD – University of Pittsburgh
Location: Hall D

5:10 – 5:31 p.m. Targeting Regulatory T Cells for Therapeutic Gain: Means and Mechanisms
Sergio A. Quezada, PhD – University College London

5:31 – 5:51 p.m. The TNFR2 Treg Receptor and Oncogene: Dominant Antagonistic Antibody Targeting for Cancer
Denise L. Faustman, MD, PhD – Harvard Medical School

5:51 – 6:01 p.m. Lactic acid metabolically supports the high suppressive function of tumor infiltrating regulatory T cells
McLane Watson, BS – University of Pittsburgh
Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion
Erica Stone, PhD – Wistar Institute

Neuropilin-1 Stabilizes Human Tregs in Cancer Patients Leading to More Potent Suppressive Function
Christopher A. Chuckran, BS – University of Pittsburgh School of Medicine

6:11 – 6:21 p.m.

Q&A

Concurrent Session 215: Myeloid Derived Suppressive Populations
Co-Chairs:
Dmitry I. Gabrilovich, MD, PhD – The Wistar Institute
Sourav Ghosh, PhD – Yale School of Medicine

Location: 202AB

5:10 – 5:35 p.m.

Innate Immune Checkpoints and Cancer Immunotherapy
Sourav Ghosh, PhD – Yale School of Medicine

5:35 – 6 p.m.

Regulation of Myeloid-Derived Suppressor Cells in Cancer
Dmitry I. Gabrilovich, MD, PhD – The Wistar Institute

Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy
Greg Lesinski, PhD, MPH – Winship Cancer Institute of Emory University

6:15 – 6:30 p.m.

Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostate hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
George A. Dominguez, PhD – Anixa Biosciences

Concurrent Session 216: Role of B cells in Immunotherapy and Toxicity
Co-Chairs:
Tullia C. Bruno, PhD – University of Pittsburgh
Madhav Dhodapkar, MD – Emory University

Location: East Salon ABC

5:10 – 5:15 p.m.

Introduction
Madhav Dhodapkar, MD – Emory University

5:15 – 5:35 p.m.

Role of B cells in Tumors
Tullia C. Bruno, PhD – University of Pittsburgh
5:35 – 5:55 p.m.  Role of B cells in Autoimmunity
Kavita M. Dhodapkar, MD – Emory University

5:55 – 6:10 p.m.  B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB)
Sangeetha Reddy, MD, MSci – MD Anderson Cancer Center

6:10 – 6:25 p.m.  Anti-Tumor Immune Responses in Metastatic Breast Cancer Exceptional Responder Patients
William H. Robinson, MD, PhD – Stanford University School of Medicine

6:25 – 6:30 p.m.  Closing
Tullia C. Bruno, PhD – University of Pittsburgh

6:35 – 7 p.m.  Award Ceremony
Location:  Hall D

7 – 8:30 p.m.  Poster Reception
Location:  Hall E

8:30 – 11:30 p.m.  The Checkpoints Band Party
Location:  Marriott Marquis Liberty Ballroom
Sunday, November 11, 2018

7 – 10 a.m. Registration  
Location: L St. Bridge

7 – 8 a.m. Breakfast  
Location: Hall E Foyer

7:30 – 7:35 a.m. Annual Meeting Organizer Welcome  
Dario A.A. Vignali, PhD – University of Pittsburgh  
Location: Hall D

Session 300: Update Session  
Location: Hall D

7:35 – 8:05 a.m. Cancer Immunotherapy Trials Network Update  
Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center

Concurrent Session 301: Next Generation Bispecifics and Antibody-Like Molecules  
Co-Chairs:  
Ignacio Melero, MD, PhD – FIMA - University of Navarra  
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center  
Location: Hall D

8:05 – 8:10 Introduction  
Ignacio Melero, MD, PhD – FIMA-University of Navarra

8:10 – 8:35 a.m. Next Generation T Cell Bispecific Antibodies and Fusion Proteins for Cancer Immunotherapy  
Pablo Umaña, PhD – Roche Glycart AG

8:35 – 9:00 a.m. Blinatumomab: Can We Improve Efficacy Using Checkpoint Inhibitors  
Dirk Nagorsen, MD, PhD – Amgen Inc.

9:00 – 9:25 a.m. Chimeric Antibodies in AML: Hope or Reality?  
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

9:25 – 9:40 a.m. A new immunomodulatory strategy of inhibiting the glyco-immune checkpoint axis with EAGLE technology to treat cancer  
Li Peng, PhD – Palleon Pharmaceuticals

9:40 – 9:55 a.m. FS120 mAb2, a dual agonist bispecific antibody targeting OX40 and CD137, activates T cells in
vitro and induces potent, FcγR-independent anti-tumour activity
Miguel Gaspar, PhD – F-star Biotechnology ltd

9:55 – 10:10 a.m.  Immuno-oncology tHERApy with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality
David M. Richards – Apogenix AG

10:10 – 10:15 a.m.  Closing
Farhad Ravandi, MD – University of Texas MD Anderson Cancer Center

10:15 – 10:30 a.m.  Break

Concurrent Session 302: Clinical Trials Session
Co-Chairs:
Michael Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Mario Szol, MD – Yale Cancer Center

Location: 202AB

8:10 – 8:25 a.m. Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors
Amod Sarnaik, MD – H. Lee Moffitt Cancer Center & Research

8:25 – 8:40 a.m. Infusion of TGFβ-resistant EBV-specific T-cells post cytoreductive chemotherapy is safe and associated with clinical benefit in patients with recurrent/metastatic NPC
Christopher DeRenzo, MD – St. Jude Children’s Research Hospital

8:40 – 8:55 a.m. Expert Discussant
Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center

8:55 – 9:05 a.m. Using high dimensional mass cytometry (CyTOF) and machine assisted analysis to detect biomarkers in the immunotherapy of cancer
Carsten Krieg, PhD – Medical University of South Carolina

9:05 – 9:20 a.m. Monalizumab in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): clinical and translational biomarker results
Roger Cohen – University of Pennsylvania

9:20 – 9:35 a.m. Combination of subcutaneous selicrelumab (CD40 agonist) and vanucizumab (anti-Ang2/VEGF) in patients with solid tumors demonstrates early clinical activity and a favorable safety profile
Emiliano Calvo, MD, PhD – START Madrid
9:35 – 9:50 a.m.  A phase 1, open-label, dose-escalation study of enoblituzumab in combination with pembrolizumab in patients with select solid tumors
Charu Aggarwal, MD, MPH – University of Pennsylvania

9:50 – 10:05 a.m.  Phase 2 trial of mocetinostat in combination with durvalumab in NSCLC patients with progression on prior checkpoint inhibitor therapy
Manish Patel, DO – University of Minnesota Medical Center

10:05 – 10:15 a.m.  Expert Discussant
Elad Sharon, MD, MPH – National Institutes of Health

Concurrent Session 303: Update Session
Location: Hall D

10:30 – 10:45 a.m.  Immunoscore Update
Jerome Galon, PhD – Universite Pierre Et Marie Curie, Sorbonne Universites

Concurrent Session 304: Hot Topic Symposium
Location: Hall D
Lessons from Recent Immuno-Oncology Trials - When Activity Estimation Diverges from Therapeutic Confirmation
Co-Chairs:
Helen Chen, MD – National Cancer Institute
Marc Theoret, MD – U.S. Food & Drug Administration, OHOP

10:45 – 10:50 a.m.  Introduction
Marc Theoret, MD – U.S. Food & Drug Administration, OHOP

10:50 – 11:05 a.m.  Considering Recent Clinical Failures to Inform Novel Immuno-Therapeutics Development
Jason J. Luke, MD, FACP – University of Chicago

11:05 – 11:20 a.m.  Dosing and Dosage Regimen
Renzo Canetta, MD

11:20 – 11:35 a.m.  Biomarker Selection Considerations
Roy S. Herbst, MD, PhD – Yale Cancer Center

11:35 – 11:50 a.m.  Clinical Development Strategy/Trial Design
Mario Sznol, MD – Yale Cancer Center
11:50 a.m. – 12:15 p.m.  **Panel Discussion**  
**Moderators:** Helen Chen, MD – *National Cancer Institute*  
Marc Theoret, MD – *U.S. Food & Drug Administration, OHOP*  

**Panelists:** Renzo Canetta, MD  
Roy S. Herbst, MD, PhD – *Yale Cancer Center*  
Jason J. Luke, MD, FACP – *University of Chicago*  
Rajeshwari Sridhara, PhD – *U.S. Food & Drug Administration*  
Mario Sznol, MD – *Yale Cancer Center*

12:15 – 12:20 p.m.  **Thank you for attending SITC 2018!**